Imidazole based LXR modulators
US9000022B2 · kind B2 · utility
3Cited by
15References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 25, 2013 |
| Grant date | Apr 7, 2015 |
| Priority date | — |
| Expiry date | Jul 25, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/08
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Methods of using compounds of the invention, such as compounds of Formulae IIa, IIb, IIc, or IIdand pharmaceutically acceptable salts thereof are disclosed. The compounds are useful in treating, preventing, inhibiting or ameliorating the symptoms of a disease or disorder that is modulated or otherwise affected by nuclear receptor activity, or in which nuclear receptor activity is implicated.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.